Case report on hereditary haemorrhagic telangiectasia


  • Stuti Mathur Department of ENT, DY Patil Hospital, Maharashtra, India
  • Akanksha Saberwal Department of ENT, DY Patil Hospital, Maharashtra, India
  • Yogesh Dabholkar Department of ENT, DY Patil Hospital, Maharashtra, India
  • Bhavika Verma Department of ENT, DY Patil Hospital, Maharashtra, India



Hereditary haemorrhagic telangiectasia, Antifibrolytics, Gastroduodenoscopy, Hemostasis


Osler Weber Rendu disease also known as hereditary haemorrhagic telangiectasia (HHT) is a rare autosomal dominant disorder by the presence of multiple arteriovenous malformations (AVMs) that lack intervening capillaries resulting in direct connections between arteries and veins. A 70-year-old male patient known case of hypertension; Indian origin was brought to the emergency department of our hospital with complaints of severe epistaxis. An attempt was made initially to control bleeding by ice compressions and finally anterior and posterior nasal packing was done. He gave history of similar episodes in the past often accompanied with hemetemesis and malena on and off since childhood gastroduodenoscopy was done to rule out cause for hemetemesis which showed multiple telangiectasia in fundus, body and antrum of stomach and first part of duodenum establishing the diagnosis of HHT. Patient with Osler-Weber–Rendu disease may present with uncontrolled bleeding. Resuscitation along with hemostasis is the main stay of treatment. As the bleeding occurs from malformed vessels coagulation tests are normal. Management include blood transfusion, antifibrolytics and surgical hemostasis.


Peery WH. Clinical spectrum of hereditary hemorrhagic telangiectasia (Osler-Weber-Rendu disease). Am J Med. 1987.82:989-97.

Guttmacher AE, Marchuk DA, White RI Jr. Hereditary hemorrhagic telangiectasia. N Engl J Med. 1995;333:918-24.

Shovlin CL, Guttmacher AE, Buscarini E, Faughnan ME, Hyland RH, et al. Diagnostic imaging pathways: development, dissemination, implement-tation and evaluation. Int J Quality Health Care. 2006;32(4):89-95.

Auchu H, de Chadarévian JP, Bideau A, Robert JM. Age-related clinicalprofile of hereditary hemorrhagic telangiectasia in an epidemiologically recruited population. Am J Med Genet. 1989;32:291-7.

Schmierer B, Hill CS. TGF beta-SMAD signal transduction: molecularspecificity and functional flexibility. Nat Rev Mol Cell Biol. 2007;8:970-82.

Pau H, Carney AS, Murty GE. Hereditary-haemorrhagic telangiectasia (Osler-Weber-Rendu syndrome): otorhinolaryngological manifestations. Clin Otolaryngol Allied Sci. 2001;26:93-8.

Harries PG, Brockbank MJ, Shakespeare PG, Carruth JA. Treatment ofhereditary haemorrhagic telangiectasia by the pulsed dye laser. J Laryngol Otol. 1997;111:1038-41.

Wrana JL, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of activationof the TGF-beta receptor. Nature. 1994;370:341-7.

Kjeldsen AD, Kjeldsen J. Gastrointestinal bleeding in patients with hereditary hemorrhagic telangiectasia. Am J Gastroenterol. 2000;95:415-8.

Sabbà C, Pasculli G, Lenato GM, Suppressa P, Lastella P, Memeo M, et al. Hereditary hemorrhagic telangiectasia: clinical features in ENG and ALK1 mutation carriers. J Thromb Haemost. 2007;5:1149-57.






Case Reports